Search

Your search keyword '"Altintas, Ayse"' showing total 15 results
Start Over Author "Altintas, Ayse" Publisher lippincott williams & wilkins
15 results on '"Altintas, Ayse"'

1. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.

Author

Spelman, Tim, Simoneau, Gabrielle, Hyde, Robert, Kuhelj, Robert, Alroughani, Raed, Ozakbas, Serkan, Karabudak, Rana, Yamout, Bassem I., Khoury, Samia J., Terzi, Murat, Boz, Cavit, Horakova, Dana, Havrdova, Eva Kubala, Weinstock-Guttman, Bianca, Patti, Francesco, Altintas, Ayse, Mrabet, Saloua, Gouider, Riadh, Inshasi, Jihad, and Shaygannejad, Vahid

Published
2024
Full Text
View/download PDF

3. Treatment response score to glatiramer acetate or interferon beta-1a.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Bovis, Francesca, Kalincik, Tomas, Lublin, Fred, Cutter, Gary, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Terzi, Murat, Grammond, Pierre, Bergamaschi, Roberto, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Iuliano, Gerardo, Boz, Cavit, Hupperts, Raymond, Grand'Maison, Francois, Oreja-Guevara, Celia, Van Pesch, Vincent, Cartechini, Elisabetta, Petersen, Thor, Altintas, Ayse, Soysal, Aysun, Ramo-Tello, Cristina, McCombe, Pamela, Turkoglu, Recai, Butzkueven, Helmut, Wolinsky, Jerry S, Solaro, Claudio, Sormani, Maria Pia, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Bovis, Francesca, Kalincik, Tomas, Lublin, Fred, Cutter, Gary, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Terzi, Murat, Grammond, Pierre, Bergamaschi, Roberto, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Iuliano, Gerardo, Boz, Cavit, Hupperts, Raymond, Grand'Maison, Francois, Oreja-Guevara, Celia, Van Pesch, Vincent, Cartechini, Elisabetta, Petersen, Thor, Altintas, Ayse, Soysal, Aysun, Ramo-Tello, Cristina, McCombe, Pamela, Turkoglu, Recai, Butzkueven, Helmut, Wolinsky, Jerry S, Solaro, Claudio, and Sormani, Maria Pia

Abstract

OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intra-muscular Interferon beta-1a (IFNbeta-1a)), we applied a previously published statistical method, aimed at identifying patients' profiles associated with efficacy of treatments. METHODS: Data from 2 independent multiple sclerosis datasets, a randomized study (the CombiRx trial, evaluating GA vs IFNbeta-1a and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS: The overall ARR ratio of GA vs IFNbeta-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration and EDSS) detected differential response of GA vs IFNbeta-1a: in the trial, patients with the largest benefit from GA vs IFNbeta-1a (lower score quartile) had an ARR ratio of 0.40 (95%confidence interval [CI] = 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI = 0.61-1.34) and those in the upper quartile of 1.14 (95%CI = 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSbase, with the corresponding ARR ratios of 0.58 (95% CI = 0.46-0.72), 0.92 (95% CI = 0.77-1.09) and 1.29 (95% CI = 0.97-1.71); heterogeneity p < 0.0001). CONCLUSIONS: We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFNbeta-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.

Published
2020

6. Familial occurrence and heritable connective tissue disorders in cervical artery dissection.

Author

Debette, Stéphanie, Goeggel Simonetti, Barbara, Schilling, Sabrina, Martin, Juan José, Kloss, Manja, Sarikaya, Hakan, Hausser, Ingrid, Engelter, Stefan, Metso, Tiina M, Pezzini, Alessandro, Thijs, Vincent, Touzé, Emmanuel, Paolucci, Stefano, Costa, Paolo, Sessa, Maria, Samson, Yves, Béjot, Yannick, Altintas, Ayse, Metso, Antti J, and Hervé, Dominique

Published
2014
Full Text
View/download PDF

10. Familial occurrence and heritable connective tissue disorders in cervical artery dissection

Author

Brandt, Tobias, Bersano, Anna, Germain, Dominique P, Tatlisumak, Turgut, Samson, Yves, Touzé, Emmanuel, Jung, Simon, Kloss, Manja, Caso, Valeria, Sessa, Maria, Dallongeville, Jean, Martin, Juan José, Lamy, Chantal, Sarikaya, Hakan, Engelter, Stefan, Béjot, Yannick, Leys, Didier, Paolucci, Stefano, Stapf, Christian, Arnold, Marcel, Bousser, Marie-Germaine, Pezzini, Alessandro, Tournier-Lasserve, Elisabeth, Metso, Tiina M, Chabriat, Hugues, Baumgartner, Ralf W, Frank, Michael, Altintas, Ayse, Hervé, Dominique, Goeggel, Barbara, Debette, Stéphanie, Hausser, Ingrid, Grond-Ginsbach, Caspar, Metso, Antti J, Fischer, Urs, Lichy, Christoph, Lyrer, Philippe A, Schilling, Sabrina, Grau, Armin, Thijs, Vincent, and Costa, Paolo

Subjects
610 Medicine & health, 3. Good health
Abstract

OBJECTIVE In a large series of patients with cervical artery dissection (CeAD), a major cause of ischemic stroke in young and middle-aged adults, we aimed to examine frequencies and correlates of family history of CeAD and of inherited connective tissue disorders. METHODS We combined data from 2 large international multicenter cohorts of consecutive patients with CeAD in 23 neurologic departments participating in the CADISP-plus consortium, following a standardized protocol. Frequency of reported family history of CeAD and of inherited connective tissue disorders was assessed. Putative risk factors, baseline features, and 3-month outcome were compared between groups. RESULTS Among 1,934 consecutive patients with CeAD, 20 patients (1.0%, 95% confidence interval: 0.6%-1.5%) from 17 families (0.9%, 0.5%-1.3%) had a family history of CeAD. Family history of CeAD was significantly more frequent in patients with carotid location of the dissection and elevated cholesterol levels. Two patients without a family history of CeAD had vascular Ehlers-Danlos syndrome with a mutation in COL3A1. This diagnosis was suspected in 2 additional patients, but COL3A1 sequencing was negative. Two patients were diagnosed with classic and hypermobile Ehlers-Danlos syndrome, one patient with Marfan syndrome, and one with osteogenesis imperfecta, based on clinical criteria only. CONCLUSIONS In this largest series of patients with CeAD to date, family history of symptomatic CeAD was rare and inherited connective tissue disorders seemed exceptional. This finding supports the notion that CeAD is a multifactorial disease in the vast majority of cases.

11. Abstract 3854.

Author

Debette, Stephanie, Martin, Juan Jose, Kloss, Manja, Engelter, Stefan, Metso, Tiina, Pezzini, Alessandro, Thijs, Vincent, Touze, Emmanuel, Paolucci, Stefano, Samson, Yves, Bejot, Yannick, Altintas, Ayse, Metso, Antti, Lichy, Christoph, Lamy, Chantal, Grau, Armin, Caso, Valeria, Lyrer, Philippe, Tatlisumak, Turgut, and Grond-Ginsbach, Caspar

Published
2012

13. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD

Author

Kaho B. Onomichi, Anna Tomczak, Allyson Reid, Ilya Kister, Jacinta M. Behne, Megan Kenneally Behne, Claire S Riley, Leticia Tornes, Julia J. Schubert, Jeffrey A. Cohen, Michael J. Levy, Devin S. Mullin, Jeffrey Bennett, Lawrence J. Cook, Renee R. Rodriguez, Terrence F. Blaschke, Zoe Rimler, Anthony Traboulsee, Jessica S. Alvey, Casey Engel, Derek W. Blackway, Anne Rumpf, Libby Levine, Anna Marie Jolley, Jennifer L. Sedlak, Ruth Johnson, Tanuja Chitnis, Katrina McMullen, Nancy Nealon, Brie Marron, Renee Kuhn, Mason Kruse-Hoyer, Brian Coords, Andrew W. Russo, Angela Greer, Stephen McKechnie, Terry J. Smith, Sarah M. Planchon, Melanie Marcille, Lilyana Amezcua, F. Rene Enriquez, Michael R. Yeaman, Pavle Repovic, Maureen A. Mealy, Ilana Katz Sand, Jeff Yearley, Erika Amundson, May H. Han, Lisa Eunyoung Lee, John W. Rose, Melissa Pederson, Daniel W. Behne, Robert Carruthers, Katherine E. Nelson, Ana Pruitt, Jessica Coleman, Eric C. Klawiter, Judy Sheard, Diane Ivancic, Nancy L. Sicotte, Myka Barnes-Garcia, İÜC, Neurology, Ayşe Altıntaş ( ORCID 0000-0002-8524-5087 & YÖK ID 11611), Cook, Lawrence J., Rose, John W., Alvey, Jessica S., Jolley, Anna Marie, Kuhn, Renee, Marron, Brie, Pederson, Melissa, Enriquez, Rene, Yearley, Jeff, McKechnie, Stephen, Han, May H., Tomczak, Anna J., Levy, Michael, Mealy, Maureen A., Coleman, Jessica, Bennett, Jeffrey L., Johnson, Ruth, Barnes-Garcia, Myka, Traboulsee, Anthony L., Carruthers, Robert L., Lee, Lisa Eunyoung, Schubert, Julia J., McMullen, Katrina, Kister, Ilya, Rimler, Zoe, Reid, Allyson, Sicotte, Nancy L., Planchon, Sarah M., Cohen, Jeffrey A., Ivancic, Diane, Sedlak, Jennifer L., Sand, Ilana Katz, Repovic, Pavle, Amezcua, Lilyana, Pruitt, Ana, Amundson, Erika, Chitnis, Tanuja, Mullin, Devin S., Klawiter, Eric C., Russo, Andrew W., Riley, Claire S., Onomichi, Kaho B., Levine, Libby, Nelson, Katherine E., Nealon, Nancy M., Engel, Casey, Kruse-Hoyer, Mason, Marcille, Melanie, Tornes, Leticia, Rumpf, Anne, Greer, Angela, Behne, Megan Kenneally, Rodriguez, Renee R., Behne, Daniel W., Blackway, Derek W., Coords, Brian, Blaschke, Terrence F., Sheard, Judy, Smith, Terry J., Behne, Jacinta M., Yeaman, Michael R., Abboud, Hesham, Aktas, Orhan, Altintas, Ayse, Apiwattanakul, Metha, Asgari, Nasrin, Banwell, Brenda, Bichuetti, Denis, Bowen, James, Broadley, Simon, Bruck, Wolfgang, Cabre, Philippe, Cohen, Jeffrey, De Seze, Jerome, Delgado-Garcia, Guillermo, Basuroski, Irena Dujmovic, Fujihara, Kazuo, Goodman, Andrew, Havla, Joachim, Hellwig, Kerstin, Hintzen, Rogier, Hooper, D. Craig, Iorio, Raffaele, Jacob, Anu, Jarius, Sven, Jimenez Arango, Jorge Andres, John, Gareth, Kim, Ho Jin, Kim, Sung Min, Kimbrough, Dorian J., Kissani, Najib, Kleiter, Ingo, Lana-Peixoto, Marco, Leite, M. Isabel, Liu, Yaou, Lublin, Fred, Maiga, Youssoufa, Mao-Draayer, Yang, Marignier, Romain, Matiello, Marcelo, Momtazee, Callene, Morrow, Mark, Nakashima, Ichiro, O'Connor, Kevin, Oreja-Guevara, Celia, Palace, Jacqueline, Pandit, Lekha, Paul, Friedemann, Prayoonwiwat, Naraporn, Probstel, Anne-Katrin, Qian, Peiqing, Quan, Chao, Ringelstein, Marius, Rivera, Victor, Rotstein, Dalia L., Ruprecht, Klemens, Sa, Maria Jose, Saiz, Albert, Serguera, Che, Shosha, Eslam, Siritho, Sasitorn, Siva, Aksel, Soto de Castillo, Ibis, Stuve, Olaf, Tenembaum, Silvia, Villoslada, Pablo, Wingerchuk, Dean, Wuerfel, Jens, Yeh, E. Ann, Zamvil, Scott S., Langer-Gould, Annette, School of Medicine, and Department of Neurology

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, Pediatrics, Biomedical Research, Internationality, MEDLINE, Article, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Epidemiology, medicine, Humans, Spectrum disorder, Longitudinal Studies, Intersectoral Collaboration, International research, Neuromyelitis optica, business.industry, Neuromyelitis Optica, Middle Aged, medicine.disease, 3. Good health, 030104 developmental biology, Neurology, Cohort, Medicine, Clinical neurology, Neurosciences, Female, Observational study, Neurology (clinical), Function and Dysfunction of the Nervous System, business, 030217 neurology & neurosurgery, Neuromyelitis-optica, Diagnostic-criteria, Prevalence, Multicenter, Disorders, Features, Cohort study
Abstract

Objective to develop a resource of systematically collected, longitudinal clinical data and biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder (NMOSD) epidemiology, pathogenesis, and treatment. Methods to illustrate its research-enabling purpose, epidemiologic patterns and disease phenotypes were assessed among enrolled subjects, including age at disease onset, annualized relapse rate (ARR), and time between the first and second attacks. Results as of December 2017, the Collaborative International Research in Clinical and Longitudinal Experience Study (CIRCLES) had enrolled more than 1,000 participants, of whom 77.5% of the NMOSD cases and 71.7% of the controls continue in active follow-up. Consanguineous relatives of patients with NMOSD represented 43.6% of the control cohort. Of the 599 active cases with complete data, 84% were female, and 76% were anti-AQP4 seropositive. The majority were white/Caucasian (52.6%), whereas blacks/African Americans accounted for 23.5%, Hispanics/Latinos 12.4%, and Asians accounted for 9.0%. The median age at disease onset was 38.4 years, with a median ARR of 0.5. Seropositive cases were older at disease onset, more likely to be black/African American or Hispanic/Latino, and more likely to be female. Conclusions collectively, the CIRCLES experience to date demonstrates this study to be a useful and readily accessible resource to facilitate accelerating solutions for patients with NMOSD., The Guthy-Jackson Charitable Foundation, The CIRCLES Project

Published
2019

14. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.

Author

Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, Vodehnalova K, Ozakbas S, Eichau S, Duquette P, Kalincik T, Patti F, Boz C, Terzi M, Yamout BI, Lechner-Scott J, Sola P, Skibina OG, Barnett M, Onofrj M, Sá MJ, McCombe PA, Grammond P, Ampapa R, Grand'Maison F, Bergamaschi R, Spitaleri DLA, Van Pesch V, Cartechini E, Hodgkinson S, Soysal A, Saiz A, Gresle M, Uher T, Maimone D, Turkoglu R, Hupperts RM, Amato MP, Granella F, Oreja-Guevara C, Altintas A, Macdonell RA, Castillo-Trivino T, Butzkueven H, Alroughani R, and Jokubaitis VG

Abstract

Objective: To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort., Methods: Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses., Results: We included 1998 pregnancies from 1619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% CI 0.27-0.32), fell to 0.19 (0.14-0.24) in third trimester, and increased to 0.59 (0.51-0.67) in early postpartum. Among women who used fingolimod or natalizumab, ARR before pregnancy was 0.37 (0.28-0.49) and 0.29 (0.22-0.37), respectively, and increased during pregnancy. Intrapartum ARR decreased with preconception dimethyl fumarate use. ARR spiked after delivery across all DMT groups. Natalizumab continuation into pregnancy reduced the odds of relapse during pregnancy (OR 0.76 per month [0.60-0.95], p=0.017). DMT re-initiation with natalizumab protected against postpartum relapse (HR 0.11 [0.04-0.32], p<0.0001). Breastfeeding women were less likely to relapse (HR 0.61 [0.41-0.91], p=0.016). 5.6% of pregnancies were followed by confirmed disability progression, predicted by higher relapse activity in pregnancy and postpartum., Conclusion: Intrapartum and postpartum relapse probabilities increased among women with MS after natalizumab or fingolimod cessation. In women considered to be at high relapse risk, use of natalizumab before pregnancy and continued up to 34 weeks gestation, with early re-initiation after delivery is an effective option to minimize relapse risks. Strategies of DMT use have to be balanced against potential fetal/neonatal complications., (© 2021 American Academy of Neurology.)

Published
2021
Full Text
View/download PDF

15. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.

Author

Bovis F, Kalincik T, Lublin F, Cutter G, Malpas C, Horakova D, Havrdova EK, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Izquierdo G, Eichau S, Patti F, Terzi M, Grammond P, Bergamaschi R, Sola P, Ferraro D, Ozakbas S, Iuliano G, Boz C, Hupperts R, Grand'Maison F, Oreja-Guevara C, van Pesch V, Cartechini E, Petersen T, Altintas A, Soysal A, Ramo-Tello C, McCombe P, Turkoglu R, Butzkueven H, Wolinsky JS, Solaro C, and Sormani MP

Subjects
Adult, Cohort Studies, Databases, Factual trends, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Treatment Outcome, Adjuvants, Immunologic administration & dosage, Glatiramer Acetate administration & dosage, Immunosuppressive Agents administration & dosage, Interferon beta-1a administration & dosage, Multiple Sclerosis, Relapsing-Remitting diagnosis, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Objective: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments., Methods: Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors., Results: The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p < 0.0001)., Conclusions: We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice., (© 2020 American Academy of Neurology.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results